Childhood Laryngeal Tumors
Laryngeal Tumors in children and adolescents
TREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 26, 2025. Captured 2026-09-09.
Squamous cell carcinoma of the larynx in children is managed by surgery and radiation therapy, as in adults with carcinoma at this site.[4,5] Laser surgery may be the initial treatment used for these lesions. Outcomes of pediatric patients with squamous cell carcinoma of the larynx are similar to those reported for adult patients.[4] For more information about the treatment of laryngeal cancer in adults, see Laryngeal Cancer Treatment.
Sources: 4 · 5 · 4 · Laryngeal Cancer Treatment
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 26, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 26, 2025. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
Sources: 6 · Rare Diseases Act of 2002
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
Sources: 9
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
Information about these tumors may also be found in sources relevant to adults with cancer, such as Laryngeal Cancer Treatment.
Sources: Laryngeal Cancer Treatment
Source: Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 26, 2025. Captured 2026-09-09.
Primary treatment for papillomatosis is surgical ablation with laser vaporization.[9] Frequent recurrences are common. Lung involvement, although rare, can occur.[6]
Evidence (surgery):
A single-institution retrospective analysis evaluated 121 children with respiratory papillomatosis. The age at initial operation was 4.3 years (±2.9 years), and 47.9% of patients (58 of 121) experienced a recurrence and underwent surgical treatment after the age of 14 years.[10]
Sources: 10
A single-institution retrospective analysis evaluated 121 children with respiratory papillomatosis. The age at initial operation was 4.3 years (±2.9 years), and 47.9% of patients (58 of 121) experienced a recurrence and underwent surgical treatment after the age of 14 years.[10]
At follow-up, 5% of the patients (6 of 121) had died, 41.3% of the patients (50 of 121) had been recurrence free for 5 years or longer (cured group), and 53.7% of the patients (65 of 121) experienced a recurrence in the previous 5 years (recurrent group).
There were no significant differences in sex, age at initial operation, or adjuvant therapy between the cured and recurrent groups of patients.
In the recurrent group, there was a higher incidence of overall operation frequency, aggressive disease, tracheal dissemination of the papilloma, and HPV infection.
If a patient requires more than four surgical procedures per year, other interventions may be necessary. The following therapies are under investigation:
Systemic bevacizumab produced good results with minimal toxicity in a report of two patients with aggressive recurrent respiratory papillomatosis.[11] In another report of seven children treated with bevacizumab, continued responses were noted and subsequent surgical debridements were avoided in most patients. Of the seven patients, five did not require surgical debridement after the initiation of bevacizumab. Four of these five patients had previously required between four and ten debridements per year. Follow-up for these patients was between 8 months and 3.5 years. No serious adverse events were reported.[12] In a study of 24 patients with recurrent respiratory papillomatosis, 15 had juvenile-onset disease. Patients were treated with systemic bevacizumab (7.5–10 mg/kg) every 3 to 4 weeks. All patients had a reduction in the number and size of lesions after three doses, excluding one patient who was lost to follow-up. Voice outcomes were improved in 87.5% of patients, as measured by Voice Handicap Index-30 (VHI) or pediatric VHI. No grade 3 Common Terminology Criteria for Adverse Events were reported. However, follow-up was limited to a maximum of 14 months after initiation of therapy and 10 months after discontinuation of bevacizumab.[13] In a study of 17 adult patients (12 with juvenile-onset recurrent or refractory respiratory papillomatosis) who received systemic bevacizumab, the number of recurrences and surgeries were significantly reduced compared with previous treatments.[14]
Interferon therapy.[15]
Sources: 15
Immunotherapy with HspE7, a recombinant fusion protein that has shown activity in other HPV-related diseases. A pilot study suggested a marked increase in the amount of time between surgeries.[16]
Sources: 16
Laser therapy combined with intralesional bevacizumab.[17]
Sources: 17
Intralesional cidofovir has been studied. However, its effectiveness has not been conclusively demonstrated.[18]
Sources: 18
Checkpoint inhibitors, such as PD-1 inhibitors, are currently being investigated.[19]
Sources: 19
Reports with small numbers of patients have documented that in selected cases, the administration of a quadrivalent HPV vaccine was associated with complete remission and an increase in the intersurgical interval.[20,21] In contrast, other reports have not documented a therapeutic effect of the quadrivalent HPV vaccine.[22]
Source: Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 26, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Laryngeal Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Source: Childhood Laryngeal Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of laryngeal tumors. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and who specialize in certain areas of medicine. Other specialists may include:
pediatrician
Sources: pediatrician
pediatric surgeon
Sources: pediatric surgeon
radiation oncologist
Sources: radiation oncologist
pathologist
Sources: pathologist
ear, nose, and throat specialist
Sources: ear, nose, and throat specialist
social worker
Sources: social worker
rehabilitation specialist
Sources: rehabilitation specialist
psychologist
Sources: psychologist
child-life specialist
Sources: child-life specialist
There are different types of treatment for children with laryngeal tumors. You and your child's care team will work together to decide on treatment. Many factors will be considered, such as your child's overall health and whether the tumor is newly diagnosed or has come back.
Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.
Source: Childhood Laryngeal Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Laser surgery uses a laser beam (a narrow beam of intense light) to destroy the cancer cells.
For laryngeal cancer that is likely to spread, external radiation therapy is also used. This treatment uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
Source: Childhood Laryngeal Tumors (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 8, 2025. Captured 2026-09-09.
Laser surgery, which uses a laser beam (a narrow beam of intense light) to destroy cancer cells, may be used to treat newly diagnosed papillomatosis or other benign tumors.
For laryngeal papillomatosis that comes back after being removed by laser surgery four times in one year, treatment may include:
Immunotherapy. Immunotherapy uses the patient's immune system to fight disease.
Laryngeal Tumors in children and adolescents